Header Logo

Connection

VARSHA V GANDHI to Animals

Back to Details
This is a "connection" page, showing publications VARSHA V GANDHI has written about Animals.
VARSHA V GANDHI
Connection Strength
0.822
Animals
  1. Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. Blood Cancer J. 2022 05 20; 12(5):80.
    View in: PubMed
    Score: 0.036
  2. Development and characterization of prototypes for in?vitro and in?vivo mouse models of ibrutinib-resistant CLL. Blood Adv. 2021 08 24; 5(16):3134-3146.
    View in: PubMed
    Score: 0.034
  3. Ibrutinib combinations in CLL therapy: scientific rationale and clinical results. Blood Cancer J. 2021 04 29; 11(4):79.
    View in: PubMed
    Score: 0.033
  4. Ataxia-telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma. Haematologica. 2021 02 01; 106(2):495-512.
    View in: PubMed
    Score: 0.033
  5. Activation of ATM kinase by ROS generated during ionophore-induced mitophagy in human T and B cell malignancies. Mol Cell Biochem. 2021 Jan; 476(1):417-423.
    View in: PubMed
    Score: 0.032
  6. Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia. 2018 04; 32(4):920-930.
    View in: PubMed
    Score: 0.026
  7. Duvelisib: a phosphoinositide-3 kinase d/? inhibitor for chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2017 May; 26(5):625-632.
    View in: PubMed
    Score: 0.025
  8. Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells. Oncotarget. 2017 Mar 07; 8(10):16259-16274.
    View in: PubMed
    Score: 0.025
  9. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma. Expert Rev Hematol. 2017 Jan; 10(1):1-8.
    View in: PubMed
    Score: 0.024
  10. Reactivation of Smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of Smac mimetic. Oncotarget. 2016 Jun 28; 7(26):39458-39472.
    View in: PubMed
    Score: 0.024
  11. Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma. Clin Cancer Res. 2017 Jan 01; 23(1):181-192.
    View in: PubMed
    Score: 0.024
  12. Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma. Oncotarget. 2016 Jan 19; 7(3):3461-76.
    View in: PubMed
    Score: 0.023
  13. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells. Neoplasia. 2015 Mar; 17(3):289-300.
    View in: PubMed
    Score: 0.022
  14. Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells. Blood. 2015 Feb 12; 125(7):1126-36.
    View in: PubMed
    Score: 0.021
  15. Targeting the apoptosis pathway in hematologic malignancies. Leuk Lymphoma. 2014 Sep; 55(9):1980-92.
    View in: PubMed
    Score: 0.020
  16. Mechanism-based combinations with Pim kinase inhibitors in cancer treatments. Curr Pharm Des. 2014; 20(42):6670-81.
    View in: PubMed
    Score: 0.020
  17. Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S317-29.
    View in: PubMed
    Score: 0.019
  18. Bcl-2 antagonists: a proof of concept for CLL therapy. Invest New Drugs. 2013 Oct; 31(5):1384-94.
    View in: PubMed
    Score: 0.019
  19. Meeting report: leaders in translational cancer research meet in Udaipur, a historical town of India: an International Symposium onTranslational Cancer Research: Cancer Prevention. Udaipur, Rajasthan, India, december 16-19, 2011. Anticancer Res. 2013 Apr; 33(4):1777-81.
    View in: PubMed
    Score: 0.019
  20. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma. Blood. 2012 Oct 25; 120(17):3491-500.
    View in: PubMed
    Score: 0.018
  21. Bax and Bak are required for apogossypolone, a BH3-mimetic, induced apoptosis in chronic lymphocytic leukemia cells. Leuk Lymphoma. 2013 May; 54(5):1097-100.
    View in: PubMed
    Score: 0.018
  22. ROS-activated anticancer prodrugs: a new strategy for tumor-specific damage. Ther Deliv. 2012 Jul; 3(7):823-33.
    View in: PubMed
    Score: 0.018
  23. Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2012 Apr; 21(4):409-23.
    View in: PubMed
    Score: 0.018
  24. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood. 2011 Jul 21; 118(3):693-702.
    View in: PubMed
    Score: 0.017
  25. Yet another nucleoside analog for pancreatic cancer. Gastroenterology. 2011 Feb; 140(2):400-4.
    View in: PubMed
    Score: 0.016
  26. Inflammation and survival pathways: chronic lymphocytic leukemia as a model system. Biochem Pharmacol. 2010 Dec 15; 80(12):1936-45.
    View in: PubMed
    Score: 0.016
  27. City of temples discusses signaling templates in cancer cells. Third International Symposium on Translational Cancer Research: Cell Signaling & Cancer Therapy. Bhubaneswar, Orissa, India, December 18th through 21st, 2009. Anticancer Res. 2010 Jun; 30(6):2477-80.
    View in: PubMed
    Score: 0.016
  28. Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood. 2010 Aug 19; 116(7):1083-91.
    View in: PubMed
    Score: 0.015
  29. Chain termination and inhibition of mammalian poly(A) polymerase by modified ATP analogues. Biochem Pharmacol. 2010 Mar 01; 79(5):669-77.
    View in: PubMed
    Score: 0.015
  30. Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma. Expert Opin Investig Drugs. 2006 Dec; 15(12):1601-13.
    View in: PubMed
    Score: 0.012
  31. The DLEU2/miR-15a/miR-16-1 cluster shapes the immune microenvironment of chronic lymphocytic leukemia. Blood Cancer J. 2024 10 23; 14(1):168.
    View in: PubMed
    Score: 0.011
  32. DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia. Blood Adv. 2023 11 14; 7(21):6685-6701.
    View in: PubMed
    Score: 0.010
  33. Plasma and cellular pharmacology of 8-chloro-adenosine in mice and rats. Cancer Chemother Pharmacol. 2002 Aug; 50(2):85-94.
    View in: PubMed
    Score: 0.009
  34. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine. J Hematol Oncol. 2021 04 26; 14(1):70.
    View in: PubMed
    Score: 0.008
  35. Purine and pyrimidine nucleoside analogs. Cancer Chemother Biol Response Modif. 2001; 19:21-45.
    View in: PubMed
    Score: 0.008
  36. Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia. Cancer Immunol Res. 2019 12; 7(12):2036-2051.
    View in: PubMed
    Score: 0.007
  37. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma. Cancer Res. 2019 07 01; 79(13):3251-3267.
    View in: PubMed
    Score: 0.007
  38. Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma. 2017 09; 58(9):1-17.
    View in: PubMed
    Score: 0.006
  39. Pharmacology of purine nucleoside analogues. Hematol Cell Ther. 1996 Dec; 38 Suppl 2:S67-74.
    View in: PubMed
    Score: 0.006
  40. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol. 1996 Oct; 23(5 Suppl 10):3-15.
    View in: PubMed
    Score: 0.006
  41. Preclinical characteristics of gemcitabine. Anticancer Drugs. 1995 Dec; 6 Suppl 6:7-13.
    View in: PubMed
    Score: 0.006
  42. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995 Aug; 22(4 Suppl 11):3-10.
    View in: PubMed
    Score: 0.006
  43. Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells. Semin Oncol. 1995 Aug; 22(4 Suppl 11):61-7.
    View in: PubMed
    Score: 0.006
  44. Elevated cyclin A associated kinase activity promotes sensitivity of metastatic human cancer cells to DNA antimetabolite drug. Int J Oncol. 2015 Aug; 47(2):782-90.
    View in: PubMed
    Score: 0.005
  45. Cytotoxicity, metabolism, and mechanisms of action of 2',2'-difluorodeoxyguanosine in Chinese hamster ovary cells. Cancer Res. 1995 Apr 01; 55(7):1517-24.
    View in: PubMed
    Score: 0.005
  46. Evolution of the arabinosides and the pharmacology of fludarabine. Drugs. 1994; 47 Suppl 6:30-8.
    View in: PubMed
    Score: 0.005
  47. Fludarabine inhibits DNA replication: a rationale for its use in the treatment of acute leukemias. Leuk Lymphoma. 1994; 14 Suppl 2:3-9.
    View in: PubMed
    Score: 0.005
  48. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013 Jan 01; 19(1):279-90.
    View in: PubMed
    Score: 0.005
  49. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012 Feb 02; 119(5):1182-9.
    View in: PubMed
    Score: 0.004
  50. Metabolism and action of fludarabine phosphate. Semin Oncol. 1990 Oct; 17(5 Suppl 8):3-17.
    View in: PubMed
    Score: 0.004
  51. Forodesine: review of preclinical and clinical data. Future Oncol. 2010 Aug; 6(8):1211-7.
    View in: PubMed
    Score: 0.004
  52. The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo. Neoplasia. 2010 May; 12(5):366-75.
    View in: PubMed
    Score: 0.004
  53. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009 Nov 12; 114(20):4441-50.
    View in: PubMed
    Score: 0.004
  54. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood. 2009 Jul 30; 114(5):1029-37.
    View in: PubMed
    Score: 0.004
  55. Identification and characterization of [3H]nitrendipine binding sites in rat spinal cord. J Pharmacol Exp Ther. 1988 Nov; 247(2):473-80.
    View in: PubMed
    Score: 0.003
  56. A novel kappa agonist inhibits [3H]nimodipine binding to a Ca++ channel receptor protein in rat brain. Biochem Biophys Res Commun. 1987 Dec 31; 149(3):1042-8.
    View in: PubMed
    Score: 0.003
  57. Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct; 48(10):1922-30.
    View in: PubMed
    Score: 0.003
  58. miRNAs and their potential for use against cancer and other diseases. Future Oncol. 2007 Oct; 3(5):521-37.
    View in: PubMed
    Score: 0.003
  59. All pathways to cancer apoptosis meeting in Thiruvananthapuram (India). Cell Death Differ. 2006 Dec; 13(12):2163-4.
    View in: PubMed
    Score: 0.003
  60. Analysis of Y chromosome nucleolar organizer mutants in Drosophila melanogaster. Biochem Biophys Res Commun. 1982 Jan 29; 104(2):778-84.
    View in: PubMed
    Score: 0.002
  61. New nucleoside analogues in clinical development. Cancer Chemother Biol Response Modif. 2002; 20:37-58.
    View in: PubMed
    Score: 0.002
  62. Fludarabine phosphate: a new active agent in hematologic malignancies. Semin Hematol. 1994 Jan; 31(1):28-39.
    View in: PubMed
    Score: 0.001
  63. X chromosome nucleolus organizer mutants which alter major type I repeat multiplicity in Drosophila melanogaster. Mol Gen Genet. 1983; 190(3):438-43.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.